Journey of Relapsed or Refractory Multiple Myeloma (RRMM) after Quadruple-Class Exposure (QCEx): Poor Outcomes and High Attrition

Puntos clave

• Patients with relapsed refractory multiple myeloma (RRMM) experience significant treatment-related attrition after quadruple-class exposure.
• Outcomes highlight a concerning trend, with over 60% reporting inadequate response to therapies after QCEx.
• Observational analysis reveals patterns in treatment efficacy and patient experiences across multiple clinical settings.
• These findings emphasize the urgent need to reevaluate treatment strategies for enhancing patient outcomes in RRMM.